<?xml version="1.0" encoding="UTF-8"?>
<p>It was suspected that COVID-19 patients who are receiving these agents might be at increased risk for adverse outcomes, but there is no clinical evidence that supports such speculation. Conversely, ARBs were proposed to have potential protective effects based on their mechanism of action [
 <xref rid="R9" ref-type="bibr">9</xref>], but there is no conclusive evidence to support this hypothesis. Multiple experts and guidelines recommended that patients who are already on ACEI or ARB should continue treatment with these agents if there is no other reason for discontinuation (e.g., hypotension, acute kidney injury (AKI)) [
 <xref rid="R10" ref-type="bibr">10</xref>].
</p>
